Aegerion Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

AEGR 26.04 +0.53 (2.08%)
price chart
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
What: Shares of Aegerion Pharmaceuticals (NASDAQ: AEGR ) , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ, after the company ...
Aegerion Pharmaceuticals Acquires Myalept(TM) From AstraZeneca  GlobeNewswire (press release)
Aegerion Pharma Buys Drug From AstraZeneca for $325M  Mergers & Acquisitions - The Middle Market
Related articles »  
Aegerion Pharmaceuticals, Inc. Soars After Sarissa Capital Discloses Stake
The shares of Aegerion Pharmaceuticals surged after Sarissa Capital Management disclosed its stake in the company. The stock was trading at $25.70 per share, up by more than 8% to $25.87 per share at the time of this writing around 2:33 in the ...
Activist Discloses 5.7% Stake In Aegerion Pharmaceuticals  Benzinga
Form SC 13D Aegerion Pharmaceuticals Filed by: Sarissa Capital Management LP  StreetInsider.com
Analysts Set Aegerion Pharmaceuticals Target Price at $38.29 (NASDAQ:AEGR)
Aegerion Pharmaceuticals logo Aegerion Pharmaceuticals (NASDAQ:AEGR) has been given a consensus rating of �Hold� by the eleven analysts that are presently covering the company, American Banking News reports. Two investment analysts have rated ...
Perilous Reversal Stock: Aegerion Pharmaceuticals (AEGR)
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Aegerion Pharmaceuticals ...
Aegerion Pharmaceuticals to Present at the 2015 Leerink Global Healthcare ...
CAMBRIDGE, Mass., Feb. 5, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases ...
Townsquare Media Inc, Aegerion Pharmaceuticals, Inc.: Tricadia Capital ...
Another filing revealed that Alex Denner's Sarissa Capital Management has entered a new position in Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR). The fund's new holding consists of around 1.6 million common shares, which amounts to 5.76% of the ...
Aegerion Pharmaceuticals Rating Reiterated by Zacks (AEGR)
Aegerion Pharmaceuticals (NASDAQ:AEGR) last announced its earnings results on Thursday, February 26th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.03.
Aegerion Pharmaceuticals, Inc. (AEGR) & The GEO Group Inc (GEO): Scopia ...
Scopia Capital Management has disclosed in a recent regulatory filing with the Security and Exchange Commission that it has acquired 4.2 million shares of Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a $900 million market cap biopharmaceutical ...
Why Aegerion Pharmaceuticals (AEGR) Stock Is Down Today  TheStreet.com
Related articles »  
Aegerion Pharmaceuticals (AEGR) Is Today's Dead Cat Bounce Stock
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Trade-Ideas LLC identified Aegerion Pharmaceuticals ...
Meet The Biopharma Stock That Lost 34% Last Week  Benzinga
Aegerion Downgraded As Stock Sheds 41% On Disappointing Q3 Results  Bidness ETC
Related articles »  
Aegerion Pharmaceuticals Observes Rare Disease Day
CAMBRIDGE, Mass., Feb. 28, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare ...